BioNxt Solutions (TSE:BNXT)
:BNXT
Want to see TSE:BNXT full AI Analyst Report?
BNXT Stock Chart & Stats
C$0.64
-C$0.02(-3.85%)
At close: 4:00 PM EST
C$0.64
-C$0.02(-3.85%)
Day’s Range― - ―
52-Week RangeC$0.34 - C$1.10
Previous CloseN/A
Volume110.36K
Average Volume (3M)80.86K
Market Cap
C$50.68M
Enterprise ValueC$59.17M
Total Cash (Recent Filing)C$12.07K
Total Debt (Recent Filing)C$6.30M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding129,959,350
10 Day Avg. Volume59,081
30 Day Avg. Volume80,860
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)-8.07
Price to Sales (P/S)0.00
P/FCF Ratio-14.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform-focused Drug-delivery ModelA platform emphasis on alternative dosage forms and delivery technologies enables multiple productization and licensing paths. Reformulating existing APIs can shorten development timelines and reduce novelty-driven regulatory risk, supporting durable licensing and partnership revenue opportunities.
Lean Organizational StructureA headcount of 25 implies a lean cost base and operational agility, which can materially extend runway versus larger peers. Sustained low fixed overhead supports efficient R&D execution and allows management to preserve cash while advancing platform development milestones.
Evidence Of Reduced Cash Burn Versus Earlier YearsDocumented improvement in cash burn from prior years suggests management has executed cost control steps. Durable reductions in operating cash outflows increase odds of reaching development inflection points without immediate dilutive capital raises, improving strategic optionality.
Bears Say
Zero Recent Revenue And Declining SalesRevenue collapsing to effectively zero removes internal funding for R&D and commercialization, preventing validation of the business model. Absent commercial receipts, the company remains dependent on external financing or licensing to support operations and prove demand for its platform.
Persistent Negative Operating And Free Cash FlowSustained negative operating and free cash flow of about -$4.5M TTM materially depletes liquidity and forces reliance on financing. With limited self-funding, the company faces ongoing dilution risk and constrained ability to invest in clinical or commercial scale-up absent external capital.
Negative Shareholder Equity And Meaningful DebtA negative equity position combined with meaningful debt signals high financial stress and restricted balance-sheet flexibility. This increases refinancing and covenant risk, raises counterparty concerns, and limits the firm's ability to absorb setbacks or fund development without dilutive or costly capital.
BioNxt Solutions News
BNXT FAQ
What was BioNxt Solutions’s price range in the past 12 months?
BioNxt Solutions lowest stock price was C$0.34 and its highest was C$1.10 in the past 12 months.
What is BioNxt Solutions’s market cap?
BioNxt Solutions’s market cap is C$50.68M.
When is BioNxt Solutions’s upcoming earnings report date?
BioNxt Solutions’s upcoming earnings report date is Aug 31, 2026 which is in 81 days.
How were BioNxt Solutions’s earnings last quarter?
Currently, no data Available
Is BioNxt Solutions overvalued?
According to Wall Street analysts BioNxt Solutions’s price is currently Overvalued.
Does BioNxt Solutions pay dividends?
BioNxt Solutions does not currently pay dividends.
What is BioNxt Solutions’s EPS estimate?
BioNxt Solutions’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioNxt Solutions have?
BioNxt Solutions has 129,959,350 shares outstanding.
What happened to BioNxt Solutions’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioNxt Solutions?
Currently, no hedge funds are holding shares in TSE:BNXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioNxt Solutions
Headquartered in Vancouver, Canada, BioNxt Solutions Inc., established in 2017, operates as a bioscience company across Germany, Switzerland, Austria, Israel, and its home country. The firm focuses on developing innovative drug delivery systems, including transdermal patches and oral dissolvable films, specifically for neurological medications. It also advances psychedelic medicine applications to treat various mental health conditions such as depression, anxiety, addiction, and trauma-related stress disorder. Furthermore, BioNxt is engaged in creating point-of-care diagnostics, comprising rapid tests and biosensor screening tools, aimed at early disease detection, improved treatment efficacy, and enhanced disease management. This diagnostic portfolio features a COVID-19 PCR kit, alongside oral biosensors for peri-implantitis, H1N1 (swine flu), and H5N1 (avian flu). Complementing its development efforts, the company provides analytical testing and consulting services, and is involved in pathogen and oral health diagnostics, thin film drug formulation, and the production and formulation of psychedelic pharmaceuticals. The company adopted its current name in November 2022, having previously been known as XPhyto Therapeutics Corp.
Technical Analysis
Willow Biosciences Inc
―
Quantum Biopharma
―
MediPharm Labs
―
Avicanna
―
InnoCan Pharma
―
Options Prices
Currently, No data available
---